Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids

Journal of Allergy and Clinical Immunology

Volumn 97, Issue 1 II, 1996, Pages 169-176

  Johnson, M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; DEXAMETHASONE; DRUG METABOLITE; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; METHYLPREDNISOLONE; PROTEINASE INHIBITOR; STEROID RECEPTOR; TRIAMCINOLONE ACETONIDE;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SOLUBILITY; DRUG TISSUE LEVEL; DRUG UPTAKE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; LIPOPHILICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION;

EID: 0030048729     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(96)80217-X     Document Type: Article

References (26)

1. Barnes P.J. Adcock I.M. Anti-inflammatory actions of steroids: molecular mechanism Trends Pharmacol Sci 14 1993 436 441
2. [Abstract P1864] Högger P. Rawert L. Rohdewald P. Dissolution tissue binding and kinetics of receptor binding of inhaled glucocorticoids Eur Resp J 6 1993 584S
3. [Abstract P1735] Högger P. Bonsmann U. Rohdewald P. Efflux of glucocorticoids from human lung tissue to human plasma in vitro Eur Respir J 7 1994 382s
4. Van den Bosch J.M.M. Westermann C.J.J. Aumann J. Relationship between lung tissue and blood plasma concentrations of inhaled budesonide Biopharm Drug Dispos 14 1993 455 459
5. [Abstract P1530] Högger P. Esmailpour N. Rabe K. Distribution of inhaled fluticasone propionate between lung tissue and blood plasma in vivo Eur Respir J 8 1995 3035
6. Högger P. Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor Steroids 59 1994 597 602
7. Derendorf H. Hochhaus G. Möllmann H. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids J Clin Pharmacol 33 1993 115 123
8. Dahlberg E. Thalén A. Brattsand R. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16α, 17α-acetal-substituted glucocorticoids Mol Pharmacol 25 1983 70 78
9. Würthwein G. Rehder S. Rohdewald P. Lipophilie and Rezeptoraffinitdt von Glucocorticoiden Pharm Ztg Wiss 5 1992 2 8
10. Rohdewald P. Möllmann H.W. Hochhaus G. Affinities of glucocorticoids for glucocorticoid receptors in the human lung Agents Actions 17 1985 3 4
11. [Abstract] English A.F. Neate M.S. Quint D.J. Sareen M. Biological activities of some corticosteroids used in asthma Am J Respir Crit Care Med 149 1994 A212
12. [Abstract] Abbinante-Nissen J.M. Simpson L.G. Leikauf G.D. Corticosteroids increase secretory leukocyte protease inhibitor transcript levels in airway epithelial cells Am J Respir Crit Care Med 149 1994 A869
13. Sareen M, et al. Comparative topical potencies of corticosteroids. Eur Respir J (in press).
14. (suppl) Brattsand R. Thalén A. Roempke K. Development of new glucocorticoids with -a very high ratio between topical and systemic activities Eur J Respir Dis 63 1982 62 73
15. (Suppl) Johansson S.A. Andersson K.E. Brattsand R. Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man Eur J Respir Dis 63 1982 74 82
16. Dahl R. Lundback B. Malo J.R. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma Chest 104 1993 1352 1358
17. Ayres J.G. Bateman E.D. Lundback B. Harris T.A.J. Highdose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma Eur J Respir Dis 8 1995 579 586
18. Fabbri L. Burge P.S. Croonenborgh L. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year Thorax 48 1993 817 823
19. Barnes P.J. Inhaled glucocorticoids for asthma N Engl J Med 332 1995 868
20. Brattsand R. Selroos O. Current drugs for respiratory diseases Page C.P. Metzger W.J. Drugs and the lung 1994 Raven Press New York 101 220
21. Holliday S.M. Faulds D. Sorkin E.M. Inhaled fluticasone propionate: a review of its pharmacokinetic properties and therapeutic use in asthma Drugs 47 1994 318 331
22. Edsbäcker S. Andersson K.E. Ryrfeldt A. Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man Eur J Clin Pharmacol 29 1985 477 481
23. [Abstract] McDowall J.E. Mackie A.E. Bye A. Ventresca G.P. Very low systemic exposure to intranasal fluticasone- propionate J Allergy Clin Immunol 95 1995 194
24. [Abstract P1733] Rohdewald P. Rehder S. Plasma levels of beclomethasone dipropionate (BDP) and its 17-monopropionate metabolite (17-BMP) following BDP inhalation Eur Respir J 7 1994 382S
25. Phillipps G.H. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate Respir Med 84 suppl A 1990 19 23
26. Brattsand R. Axelsson B. New inhaled glucocorticoids Barnes P.H. New drugs for asthma vol. 2 1992 IBC Technical Services Ltd. London 192 207